According to Merck's announcement of Liptruzet on its company website, "No incremental benefit of LIPTRUZET on cardiovascular morbidity and mortality over and above that demonstrated for atorvastatin has been established."
The FDA has remained silent about its reasoning for approving Liptruzet without evidence for benefit. Additionally, in the FDA's Drug Details of Liptruzet's approval, it is stated that "There are no Therapeutic Equivalents" for the drug when, in fact, there are already similar drugs on the market that are already being prescribed worldwide.
That 'New' Merck Cholesterol Pill Undermines FDA Credibilty
The FDA Approval Of Merck's Cholesterol Lowerer, Liptruzet, Doesn't Help Its Credibility